Two children with a rare genetic condition will live very different lives because one was tested at birth and the other was not, their parents say. Marley, five, and Meadow, four months, both have ...
SMA is a rare, genetic neuromuscular condition that affects people across age groups. With treatment landscapes evolving ...
Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
Treatment Market is projected to grow at a healthy rate of around 13% by 2026. This growth is primarily driven by the increasing prevalence of SMA, growing awareness of early diagnosis and treatment, ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment ...
Novartis wins FDA approval for Itvisma gene therapy enabling treatment of SMA in patients aged two years and older, offering ...
-- Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community Mary Fiance, National Vice ...
The Centre informed the Supreme Court that guidelines to regulate explicit and harmful social media content are in the final ...
November is Prematurity Awareness Month, and one Lee’s Summit family is sharing their story of strength and hope.
The Centre on Thursday informed the Supreme Court that the Union Ministry of Information and Broadcasting is in the final ...
The U.S. Food and Drug Administration has approved gene therapy for the treatment of Spinal Muscular Atrophy.Itvisma (onasemnogene abeparvovec-brve), an adeno-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback